MarketFriction

Acutaas Chemicals Ltd

NSE ACUTAAS · BSE 543349 · Pharmaceuticals
₹3,196.50 -2.53%
NSE close2026-10-01
52 week range1,302.00 - 3,740.00
Market cap₹27,051 Cr.
P/E70.0
Nifty 500Nifty Smallcap 50Nifty Smallcap 100Smallcap 250 Price band 20% Delivery 51.0%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales172166225177247275308207306393433330
Expenses148140182147198206224156211243249217
Operating Profit252743304969855195151184113
OPM %14%16%19%17%20%25%28%25%31%38%42%34%
Other Income-3031182616105112
Interest132401111111
Depreciation445676788101010
Profit before tax-102437205063835896145184104
Tax %71%25%31%26%25%28%24%24%25%27%27%28%
Net Profit-17182615384563447210613475
EPS in Rs-2.552.273.411.714.565.497.635.418.8213.1916.099.07
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1601882392403415206177171,0071,3391,462
Expenses137157196198260415493589775859919
Operating Profit2331424280105123128232480543
OPM %14%16%18%17%24%20%20%18%23%36%37%
Other Income0302134-25174227
Interest33566626634
Depreciation12344101216273638
Profit before tax19283535729111282216483529
Tax %35%35%34%21%25%21%26%41%26%26%
Net Profit1218232754728349160356387
EPS in Rs40.1761.6711.1013.088.579.8711.435.8019.3843.5147.17
Dividend Payout %0%0%0%0%0%15%13%26%8%6%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%32%30%41%
Compounded Profit Growth%46%62%104%
Stock Price CAGR%39%75%151%
Return on Equity20%18%18%24%
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital221010323636374141
Reserves3756721011354865586371,2691,613
Borrowings27445459137142171336
Other Liabilities43547761110136169205227295
Total Liabilities1091552132324136597671,0961,5491,984
Fixed Assets28327985186205259427570745
CWIP11302120330125130332
Investments1322122000
Other Assets6891131133225450477543848907
Total Assets1091552132324136597671,0961,5491,984
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity298152728-1266125118292
Cash from Investing Activity-19-25-21-24-101-121-33-365-224-266
Cash from Financing Activity-7156072140-122392614
Net Cash Flow3-2-03-1820-115630
Free Cash Flow10-16-76-77-46-31-155-76-36
CFO/OP153%53%68%85%52%10%73%116%71%84%
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days83971168612911513610510599
Inventory Days768995148123150131139119149
Days Payable14815416814617215815711910399
Cash Conversion Cycle1131438880107111125121149
Working Capital Days466428345114113980123116
ROCE %38%34%27%33%24%21%16%20%32%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters38.93%39.91%39.91%35.98%35.97%35.96%35.96%32.66%32.66%32.66%32.66%32.66%
FIIs7.15%11.66%8.98%12.93%13.87%15.52%16.48%16.94%16.84%16.67%19.48%21.61%
DIIs5.95%7.58%6.80%14.81%19.93%20.23%18.31%22.38%22.59%21.70%19.60%19.55%
Government0.00%0.00%0.00%0.00%0.00%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public47.97%40.85%44.31%36.28%30.24%28.27%29.22%28.00%27.89%28.96%28.24%26.16%
No. of Shareholders72,89783,34495,78490,98793,39495,7561,14,0601,19,8901,08,6641,10,3631,12,9391,25,569

Fundamentals

Market Cap₹ 27,051 Cr.
Current Price₹ 3,304
Stock P/E70.0
Book Value₹ 202
ROCE31.6 %
ROE24.0 %
Dividend Yield0.08 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)41%
Compounded Profit Growth (TTM)104%
Consolidated figures.
Valuation
Market capRs 26,170 Cr
Enterprise valueRs 25,981 Cr
P/E (TTM)67.76x
Price to book15.83x
Price to sales17.90x
EV / EBITDA45.58x
EV / EBIT48.81x
EV / sales17.77x
Price to cash flow89.57x
Earnings yield1.48%
Dividend yield0.08%
P/E, 3-year average56.30x
P/B, 3-year average7.76x
P/E, 5-year average42.75x
P/B, 5-year average5.90x
Profitability
Operating margin (excl. other income)35.87%
Operating margin (incl. other income)38.97%
EBITDA margin38.99%
Pre-tax margin36.16%
Net profit margin26.42%
Net margin, latest quarter22.53%
ROE24.05%
ROCE32.27%
ROA20.17%
ROE, 3-year average15.60%
ROCE, 3-year average21.39%
ROA, 3-year average12.25%
ROE, 5-year average16.52%
ROCE, 5-year average21.66%
ROA, 5-year average12.37%
ROIC (approx.)26.84%
Tax rate26.18%
Other income / net worth2.52%
Growth
Sales growth (latest year)33.02%
Profit growth (latest year)124.47%
Sales CAGR, 3 years29.50%
Sales CAGR, 5 years31.50%
Profit CAGR, 3 years62.33%
Profit CAGR, 5 years45.84%
Sales growth QoQ-23.82%
Profit growth QoQ-43.64%
Sales growth YoY (latest quarter)59.08%
Profit growth YoY (latest quarter)67.67%
Per share
EPS (TTM)Rs 47.17
EPS (latest year)Rs 43.51
EPS (latest quarter)Rs 9.07
EPS, 3-year averageRs 24.83
EPS, 5-year averageRs 23.42
Book value per shareRs 201.97
Sales per shareRs 178.55
Cash flow per shareRs 35.69
Free cash flow per shareRs -4.40
Dividend per share (latest year)Rs 2.50
Dividend per share, 3-year averageRs 2.33
Dividend per share, 5-year averageRs 2.60
Dividends
Dividend payout5.75%
Dividend payout, 3-year average13.11%
Dividend payout, 5-year average13.53%
Efficiency
Asset turnover0.68x
Fixed asset turnover1.80x
Inventory turnover2.90x
Inventory days126 days
Debtor days99 days
Debtors turnover3.69x
Creditor days99 days
Cash conversion cycle149 days
Working capital days116 days
Leverage
Total debtRs 36 Cr
Cash and bankRs 225 Cr
Net debtRs -189 Cr
Debt to equity0.02x
Net debt / EBITDA-0.33x
Interest coverage141.20x
Current ratio (filing 2026-03-31)3.82x
Quick ratio (filing 2026-03-31)2.82x
Trade payables (filing 2026-03-31)Rs 154 Cr
Owners' fund to total sources83.35%
Debt to assets1.79%
Cash flow
Cash from Operating Activity (latest year)Rs 292 Cr
Cash from Investing Activity (latest year)Rs -266 Cr
Cash from Financing Activity (latest year)Rs 4 Cr
Net Cash Flow (latest year)Rs 30 Cr
Free cash flow (latest year)Rs -36 Cr
FCFE (approx.: FCF + change in debt)Rs -13 Cr
Cash from ops / profit, 5 years0.82x
Sales to cash flow4.58x
Statement figures
Net sales (TTM)Rs 1,462 Cr
Net sales (latest year)Rs 1,339 Cr
Sales (latest quarter)Rs 330 Cr
Operating profit excl. other income (latest year)Rs 480 Cr
Operating profit (latest quarter)Rs 113 Cr
Other income (TTM)Rs 27 Cr
EBITDA (TTM)Rs 570 Cr
PBDT (TTM)Rs 566 Cr
Profit before tax (TTM)Rs 529 Cr
Tax (latest year)Rs 126 Cr
Net profit (TTM)Rs 386 Cr
Net profit (latest year)Rs 356 Cr
Net profit (latest quarter)Rs 74 Cr
Depreciation (TTM)Rs 38 Cr
Depreciation (latest quarter)Rs 10 Cr
Interest (TTM)Rs 4 Cr
Cost of goods sold (latest year)Rs 670 Cr
Total expenditure (latest year)Rs 859 Cr
Total income (latest year)Rs 1,381 Cr
Share capitalRs 41 Cr
ReservesRs 1,613 Cr
Shareholders' fundsRs 1,654 Cr
Total assetsRs 1,984 Cr
Net blockRs 745 Cr
Capital work in progressRs 332 Cr
InvestmentsRs 0 Cr
ReceivablesRs 363 Cr
InventoryRs 231 Cr
Other liabilitiesRs 295 Cr
Shares outstanding (crore)8.19
Ownership
Promoter holding32.66% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 67.8 is at the 53th percentile of its own 5.2-year range (median 66.0, low 50.0, high 228.3).
P/B 15.83 is at the 76th percentile (median 9.54).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodACUTAASNifty 50Difference
1 week-2.7%-2.8% +0.1 pts
1 month+0.7%-6.8% +7.5 pts
3 months-13.5%-7.6% -5.9 pts
6 months+24.9%+0.4% +24.5 pts
1 year+126.5%-9.9% +136.4 pts
2 years+279.9%-13.6% +293.4 pts
3 years+418.4%+14.2% +404.2 pts
5 years+407.4%+27.9% +379.6 pts
141 mutual fund schemes hold about ₹3,703 Cr. Over three months 31 bought more and 53 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Motilal Oswal Flexi Cap Fund2.42%343 +102%
SBI Healthcare Opp Fund4.91%284 -11%
Kotak Multi Cap Fund0.86%251 -35%
Kotak Multi Asset Allocation Fund0.94%143 -3%
ITI Small Cap Fund3.48%125 -11%
UTI Small Cap Fund2.33%123 -1%
Kotak Balanced Advantage Fund0.70%122 -11%
SBI Small Cap Fund0.28%117 -2%
HDFC Pharma and Healthcare Fund3.24%107 -18%
ICICI Pru Multi Cap Fund0.53%104 +443%
ICICI Pru Multi Cap Fund0.53%100 +443%
Kotak MNC Fund4.11%95 -16%
Bajaj Finserv Flexi Cap Fund1.02%84 +91%
SBI Large & Midcap Fund0.19%79 -47%
Baroda BNP Paribas Multi Cap Fund1.81%63 -1%
Aditya Birla SL Small Cap Fund0.94%59 +77%
PGIM India Midcap Fund0.51%57 +1%
Mahindra Manulife Small Cap Fund0.97%53 -7%
Baroda BNP Paribas Mid Cap Fund1.95%52 -6%
Union Small Cap Fund1.92%51 -5%
Motilal Oswal Focused Fund2.80%51 +21%
Kotak Consumption Fund2.92%50 -19%
Bank of India Small Cap Fund1.41%46 -44%
Union Small Cap Fund1.92%46 -5%
Bank of India Flexi Cap Fund1.45%43 -38%

Red flags

F-score 6 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2026-02-27Vijay GosarEmployees/Designated Employesell500Rs 0.11 CrMarket Sale
2026-02-18MEHUL MANSUKHBHAI KOLADIAEmployees/Designated Employesell20,000Rs 4.22 CrMarket Sale
2025-12-29Bhavesh Mansukhbhai KotadiyaEmployees/Designated Employebuy2,100Rs 0.35 CrMarket Purchase
2025-05-19Chetankumar Chhaganlal VaghasiaPromoterssell1,348,921Rs 150.40 CrMarket Sale
2025-05-19NARESHKUMAR RAMJIBHAI PATELPromoterssell1,348,921Rs 150.40 CrMarket Sale
2024-12-31RAM MOHAN LOKHANDEDirectorsell400Rs 0.09 CrMarket Sale
2024-11-11Chhagan Ramjibhai VaghasiaPromoter Groupother340,500Gift
2024-11-11Chetankumar Chhaganlal VaghasiaPromotersother340,500Gift
2024-11-06Bhanuben Chhaganlal VaghasiaPromoter Groupother342,000Gift
2024-11-06CHETANKUMAR CHHAGANLAL VAGHASIAPromotersother342,000Gift
2024-11-04CHETANKUMAR CHHAGANLAL VAGHASIAPromotersother2,937,500Gift
2024-11-04Sheetalben N. PatelPromotersother3,637,500Gift
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹330 Cr +59.4% vs Jun 2025. Net profit ₹75 Cr +70.5%.
Against our estimate for Jun 2026: sales +12.5%, profit +1.2% in line. Our estimate for Sep 2026: sales Rs 459 Cr, profit Rs 116 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-09-17Dividend - Rs 2.50 Per Share
2025-09-18Dividend - Rs 1.50 Per Share
2025-04-25Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share0.5000
2024-09-13Dividend - Rs 3 Per Share
2024-09-13Annual General Meeting
2023-09-18Dividend - Rs 3 Per Share
2023-09-18Annual General Meeting
2022-07-29Annual General Meeting/Dividend - Rs 3 Per Share
DateTypeWhat it says
2026-09-26Change in ManagementChange in Management
2026-09-26Shareholder meetingVoting results.
2026-09-24AcquisitionAcquisition
2026-09-24Shareholder meetingProceedings of Annual General Meeting held on September 24, 2026
2026-09-22Concall / analyst meetSchedule of meet
2026-09-10General UpdatesGeneral Updates
2026-09-04General UpdatesGeneral Updates
2026-08-29General UpdatesGeneral Updates
2026-08-29Record DateRecord date for the purpose of Dividend is 17-Sep-2026.
2026-08-29Shareholder meetingNotice of Annual General Meeting to be held on September 24, 2026
2026-08-28Press ReleaseA press release dated August 28, 2026, titled "Acutaas Chemicals step-down subsidiary Indichem inaugurates Semiconductor Materials Plant at Gongju, T...
2026-08-22General UpdatesGeneral Updates
2026-08-18General UpdatesGeneral Updates
2026-08-08Concall / analyst meetSchedule of meet
2026-07-28Concall / analyst meetTranscript
2026-07-24Concall / analyst meetLink of Recording
2026-07-24Investor PresentationInvestor Presentation
2026-07-24Press ReleaseA press release dated July 24, 2026, titled "Q1 FY27 Results".
2026-07-24Board meeting outcomeAcutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-20Concall / analyst meetSchedule of meet scheduled on July 24, 2026 at 04.00 P.M. (IST)
2026-07-02Change in ManagementChange in Management
2026-06-23Regulatory actionAction(s) initiated or orders passed
2026-06-22Regulatory actionAction(s) initiated or orders passed
2026-05-19General UpdatesChange in status ofAcutaas Chemicals Electrolytes Private Limited from Wholly owned Subsidiary to Subsidiary ofAcutaas Chemicals Limited
2026-05-18ResignationResignation of Director/KMP/SMP
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 100perc in previous 365 daysHigh low price variation greater than 150perc in previous 12 monthsScrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Acutaas Chemicals Ltd?

Acutaas Chemicals Ltd (ACUTAAS) has a market capitalisation of Rs 27,051 Cr. at the 2026-10-01 close.

What is the P/E ratio of Acutaas Chemicals Ltd?

Acutaas Chemicals Ltd trades at a P/E of 70.0 on trailing twelve-month profit, at the 2026-10-01 close.

What were Acutaas Chemicals Ltd's latest quarterly results?

In the Jun 2026 quarter, Acutaas Chemicals Ltd sales was Rs 330 Cr (+59.4% vs Jun 2025) and net profit was Rs 75 Cr.

What is the 52-week high and low of Acutaas Chemicals Ltd?

The 52-week high is Rs 3,740.00 and the 52-week low is Rs 1,302.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03